Abstract:Background Traditionally, the purpose of a dose-finding design in cancer is to find the maximum tolerated dose based solely on toxicity. However, for molecularly targeted agents, little toxicity may arise within the therapeutic dose range and the dose-response curves may not be monotonic. This challenges the principle that more is better, which is widely accepted for conventional chemotherapy. Methods We propose three adaptive dose-finding designs for trials evaluating molecularly targeted agents, for which the dose-response curves are unimodal or plateaued. The goal of these designs is to find the optimal biological dose, which is defined as the lowest dose with the highest rate of efficacy while safe. The first proposed design is parametric and assumes a logistic dose-efficacy curve for dose finding, the second design is nonparametric and uses the isotonic regression to identify the optimal biological dose, and the third design has the spirit of a semiparametric' approach by assuming a logistic model only locally around the current dose. Results We conducted extensive simulation studies to investigate the operating characteristics of the proposed designs. Simulation studies show that the nonparametric and semiparametric designs have good operating characteristics for finding the optimal biological dose. Limitations The proposed designs assume a binary endpoint. Extension of the proposed designs to ordinal and time-to-event endpoints is worth further investigation. Conclusion Among the three proposed designs, the nonparametric and semiparametric designs yield consistently good operating characteristics and thus are recommended for practical use. The software to implement these two designs is available for free download at http://odin.mdacc.tmc.edu/similar to yyuan/.

Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Bayesian dose-regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials

A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

Adaptive Dose Modification for Phase I Clinical Trials

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Bayesian model for early dose-finding in phase I trials with multiple treatment courses

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

Learning for Dose Allocation in Adaptive Clinical Trials with Safety Constraints

Pharmacometric and statistical considerations for dose optimization